 Timothy Ung
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroma, Acoustic | 5 | 2024 | 41 | 2.170 |
Why?
| | Brain Neoplasms | 12 | 2022 | 1137 | 1.830 |
Why?
| | Meningioma | 5 | 2022 | 77 | 1.530 |
Why?
| | Meningeal Neoplasms | 5 | 2022 | 88 | 1.530 |
Why?
| | Glioblastoma | 8 | 2019 | 311 | 1.420 |
Why?
| | Radiosurgery | 4 | 2023 | 316 | 1.100 |
Why?
| | Skull Base Neoplasms | 3 | 2022 | 24 | 0.990 |
Why?
| | Spinal Cord Neoplasms | 2 | 2023 | 39 | 0.970 |
Why?
| | Central Nervous System Cysts | 2 | 2025 | 13 | 0.900 |
Why?
| | Neurosurgical Procedures | 6 | 2022 | 168 | 0.870 |
Why?
| | Fluorescein | 4 | 2021 | 26 | 0.870 |
Why?
| | Ependymoma | 2 | 2023 | 175 | 0.840 |
Why?
| | Ear, Inner | 1 | 2023 | 44 | 0.830 |
Why?
| | Spinal Neoplasms | 1 | 2023 | 29 | 0.820 |
Why?
| | Psychosurgery | 1 | 2021 | 6 | 0.760 |
Why?
| | Third Ventricle | 2 | 2021 | 17 | 0.690 |
Why?
| | Scalp | 1 | 2020 | 34 | 0.690 |
Why?
| | Arteriovenous Malformations | 1 | 2020 | 29 | 0.690 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 77 | 0.680 |
Why?
| | Neuroendoscopy | 2 | 2020 | 20 | 0.670 |
Why?
| | Robotic Surgical Procedures | 1 | 2021 | 108 | 0.660 |
Why?
| | Laser Therapy | 1 | 2021 | 126 | 0.660 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 120 | 0.620 |
Why?
| | Neurologic Examination | 1 | 2019 | 113 | 0.620 |
Why?
| | Olfaction Disorders | 1 | 2019 | 60 | 0.600 |
Why?
| | Bleomycin | 1 | 2019 | 241 | 0.590 |
Why?
| | Smell | 1 | 2019 | 132 | 0.580 |
Why?
| | Biopsy | 3 | 2021 | 1093 | 0.550 |
Why?
| | Tectum Mesencephali | 1 | 2015 | 1 | 0.510 |
Why?
| | Ventriculostomy | 1 | 2015 | 22 | 0.500 |
Why?
| | Astrocytoma | 1 | 2015 | 120 | 0.470 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 952 | 0.460 |
Why?
| | Retrospective Studies | 17 | 2024 | 14546 | 0.440 |
Why?
| | Exosomes | 1 | 2014 | 95 | 0.430 |
Why?
| | Trigeminal Neuralgia | 2 | 2023 | 10 | 0.420 |
Why?
| | Treatment Outcome | 12 | 2024 | 10239 | 0.410 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 328 | 0.390 |
Why?
| | Preoperative Care | 1 | 2014 | 343 | 0.370 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2767 | 0.360 |
Why?
| | Proteome | 1 | 2014 | 423 | 0.340 |
Why?
| | Humans | 34 | 2025 | 128896 | 0.320 |
Why?
| | Craniotomy | 2 | 2019 | 69 | 0.270 |
Why?
| | Transcription Factors | 1 | 2014 | 1634 | 0.260 |
Why?
| | Quality of Life | 4 | 2022 | 2706 | 0.260 |
Why?
| | Facial Nerve | 2 | 2024 | 35 | 0.250 |
Why?
| | Neoplasms | 2 | 2022 | 2426 | 0.240 |
Why?
| | Audiometry, Pure-Tone | 1 | 2024 | 26 | 0.230 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2038 | 0.220 |
Why?
| | Glioma | 2 | 2018 | 347 | 0.210 |
Why?
| | Speech Perception | 1 | 2024 | 81 | 0.210 |
Why?
| | Spinal Cord | 2 | 2023 | 360 | 0.200 |
Why?
| | Skull Base | 2 | 2021 | 42 | 0.200 |
Why?
| | Male | 16 | 2025 | 63146 | 0.200 |
Why?
| | Edema | 1 | 2023 | 127 | 0.200 |
Why?
| | Hematoma, Subdural, Chronic | 1 | 2021 | 2 | 0.190 |
Why?
| | Postoperative Period | 2 | 2021 | 319 | 0.190 |
Why?
| | Cavernous Sinus | 1 | 2021 | 15 | 0.190 |
Why?
| | Corpus Callosum | 1 | 2021 | 63 | 0.180 |
Why?
| | Spine | 1 | 2023 | 155 | 0.180 |
Why?
| | Signal Transduction | 1 | 2014 | 4857 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 3 | 2018 | 3348 | 0.180 |
Why?
| | Female | 15 | 2025 | 68162 | 0.180 |
Why?
| | Neurosurgery | 1 | 2021 | 34 | 0.180 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2020 | 25 | 0.170 |
Why?
| | Middle Aged | 11 | 2025 | 30977 | 0.170 |
Why?
| | Cerebral Arteries | 1 | 2020 | 60 | 0.170 |
Why?
| | Adult | 10 | 2025 | 35361 | 0.170 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2016 | 70 | 0.160 |
Why?
| | Dacarbazine | 2 | 2016 | 99 | 0.160 |
Why?
| | Surgical Flaps | 1 | 2020 | 140 | 0.160 |
Why?
| | Face | 1 | 2020 | 168 | 0.160 |
Why?
| | Magnetic Resonance Angiography | 1 | 2020 | 237 | 0.150 |
Why?
| | Embolization, Therapeutic | 1 | 2020 | 209 | 0.150 |
Why?
| | Aged | 8 | 2024 | 22035 | 0.140 |
Why?
| | Education, Medical | 1 | 2020 | 241 | 0.140 |
Why?
| | Endovascular Procedures | 1 | 2020 | 304 | 0.130 |
Why?
| | Cranial Irradiation | 1 | 2015 | 68 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 211 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2023 | 7050 | 0.120 |
Why?
| | Patient Care Team | 1 | 2020 | 605 | 0.120 |
Why?
| | Tissue Distribution | 1 | 2015 | 295 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2017 | 253 | 0.120 |
Why?
| | Neoplasm Grading | 1 | 2015 | 277 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 203 | 0.110 |
Why?
| | Microscopy | 1 | 2015 | 140 | 0.110 |
Why?
| | Extracellular Space | 1 | 2014 | 124 | 0.110 |
Why?
| | Ligation | 1 | 2014 | 87 | 0.110 |
Why?
| | Sella Turcica | 2 | 2025 | 16 | 0.110 |
Why?
| | Nose | 1 | 2014 | 64 | 0.110 |
Why?
| | Clinical Competence | 1 | 2020 | 1020 | 0.100 |
Why?
| | Arteries | 1 | 2014 | 268 | 0.100 |
Why?
| | Adolescent | 2 | 2021 | 20197 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 699 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2603 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 382 | 0.090 |
Why?
| | Brain | 1 | 2023 | 2592 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1002 | 0.090 |
Why?
| | Immunotherapy | 1 | 2015 | 579 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1312 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1170 | 0.070 |
Why?
| | Proteomics | 1 | 2014 | 985 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1408 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1423 | 0.070 |
Why?
| | Pain | 2 | 2023 | 761 | 0.070 |
Why?
| | Salivary Glands | 1 | 2025 | 25 | 0.060 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2024 | 94 | 0.050 |
Why?
| | Young Adult | 2 | 2016 | 12286 | 0.050 |
Why?
| | Trephining | 1 | 2021 | 1 | 0.050 |
Why?
| | Hydroxyapatites | 1 | 2021 | 13 | 0.050 |
Why?
| | Durapatite | 1 | 2021 | 35 | 0.050 |
Why?
| | Esthetics | 1 | 2021 | 50 | 0.050 |
Why?
| | Postoperative Complications | 2 | 2024 | 2494 | 0.050 |
Why?
| | Supratentorial Neoplasms | 1 | 2021 | 18 | 0.050 |
Why?
| | Journal Impact Factor | 1 | 2021 | 31 | 0.040 |
Why?
| | Bibliometrics | 1 | 2021 | 53 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 198 | 0.040 |
Why?
| | Biomarkers | 2 | 2024 | 3874 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1013 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2016 | 53 | 0.030 |
Why?
| | Margins of Excision | 1 | 2016 | 38 | 0.030 |
Why?
| | Karnofsky Performance Status | 1 | 2016 | 39 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 316 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 284 | 0.030 |
Why?
| | Surgery, Computer-Assisted | 1 | 2016 | 76 | 0.030 |
Why?
| | New York | 1 | 2015 | 127 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2015 | 249 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 376 | 0.030 |
Why?
| | Sex Distribution | 1 | 2015 | 357 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 207 | 0.030 |
Why?
| | Contrast Media | 1 | 2016 | 387 | 0.030 |
Why?
| | Animals | 1 | 2015 | 34628 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1213 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1282 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 1884 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1626 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2540 | 0.020 |
Why?
| | Child | 1 | 2022 | 20824 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 9792 | 0.010 |
Why?
|
|
Ung's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|